Clinical-grade whole-genome sequencing and 3′ transcriptome analysis of colorectal cancer patients
暂无分享,去创建一个
Tariq Hassaneen Ismail | M. Ross | Z. Kingsbury | J. Stockton | T. Ismail | A. Beggs | J. James | J. Becq | M. He | S. Ward | A. Stodolna | M. Vasipalli | M. Dilworth | T. Sillo | D. Blakeway | Joanne Stockton | Toju Sillo | Mahesh Vasipalli
[1] A. Broeks,et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.
[2] S. Mirarab,et al. Sequence Analysis , 2020, Encyclopedia of Bioinformatics and Computational Biology.
[3] Steven J. M. Jones,et al. Pan-cancer analysis of whole genomes , 2020, Nature.
[4] Charles M. Perou,et al. Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches , 2020, BMC Bioinformatics.
[5] M. Wing,et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy , 2019, Cold Spring Harbor molecular case studies.
[6] William A. Pastor,et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer , 2019, Nature Communications.
[7] Jules N. A. Kerssemakers,et al. Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer , 2018, Nature Communications.
[8] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] E. Chan,et al. Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer. , 2018, Cancer research.
[10] R. Collins,et al. Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.
[11] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.
[12] The 100 000 Genomes Project: bringing whole genome sequencing to the NHS , 2018, British Medical Journal.
[13] D. Smedley,et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS , 2018, British Medical Journal.
[14] H. Nakagawa,et al. Whole genome sequencing analysis for cancer genomics and precision medicine , 2018, Cancer science.
[15] A. Abyzov,et al. Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations , 2018, Scientific Reports.
[16] Clare Verrill,et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project , 2018, Genetics in Medicine.
[17] Michelle D. Wang,et al. Mfd Dynamically Regulates Transcription via a Release and Catch-Up Mechanism , 2018, Cell.
[18] J. Kocher,et al. Early genetic aberrations in patients with sporadic colorectal cancer , 2018, Molecular carcinogenesis.
[19] R. Lothe,et al. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models , 2017, Scientific Reports.
[20] Alex H. Wagner,et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.
[21] P. Raman,et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways , 2017, Oncotarget.
[22] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[23] I. Kralj-Hans,et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study , 2017, The Lancet. Oncology.
[24] Elisa Ficarra,et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.
[25] Andy G Lynch,et al. Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data , 2017, Scientific Reports.
[26] M. Stratton,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2017, Cell.
[27] M. Gerstein,et al. Using FunSeq2 for Coding and Non‐Coding Variant Annotation and Prioritization , 2017, Current protocols in bioinformatics.
[28] Gautier Koscielny,et al. Open Targets: a platform for therapeutic target identification and validation , 2016, Nucleic Acids Res..
[29] G. Gastl,et al. Targeted Therapy of Colorectal Cancer , 2016, Oncology Research and Treatment.
[30] J. Marcickiewicz,et al. Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT , 2016, PloS one.
[31] Edwin Cuppen,et al. MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2016, Genome Medicine.
[32] Angie Duy Vo,et al. Identifying fusion transcripts using next generation sequencing , 2016, Wiley interdisciplinary reviews. RNA.
[33] R. Dzijak,et al. Nuclear myosin I regulates cell membrane tension , 2016, Scientific Reports.
[34] S. Leedham,et al. Wnt disruption in colorectal polyps – the traditional serrated adenoma enters the fray , 2016, The Journal of pathology.
[35] A. Abyzov,et al. Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation12 , 2016, Translational oncology.
[36] Philippe Rinaudo,et al. biosigner: A New Method for the Discovery of Significant Molecular Signatures from Omics Data , 2016, Front. Mol. Biosci..
[37] M. Salto‐Tellez,et al. Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer , 2016, Clinical Cancer Research.
[38] Hedi Peterson,et al. g:Profiler—a web server for functional interpretation of gene lists (2016 update) , 2016, Nucleic Acids Res..
[39] Xiaoyu Chen,et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..
[40] Eric S. Lander,et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.
[41] Steve Lee,et al. Canvas: versatile and scalable detection of copy number variants , 2016, bioRxiv.
[42] James Y. Dai,et al. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma , 2015, Human Genomics.
[43] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[44] E. Samuelson,et al. Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region , 2015, BMC Genetics.
[45] H. Kempski,et al. PAX5 alterations in genetically unclassified childhood Precursor B‐cell acute lymphoblastic leukaemia , 2015, British journal of haematology.
[46] A. Magi,et al. Detection of Genomic Structural Variants from Next-Generation Sequencing Data , 2015, Front. Bioeng. Biotechnol..
[47] Yali Dou,et al. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases , 2015, Nature Reviews Cancer.
[48] T. Rőszer,et al. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms , 2015, Mediators of inflammation.
[49] A. Ryan,et al. ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.
[50] J. Ji,et al. Oncogenic HER2 fusions in gastric cancer , 2015, Journal of Translational Medicine.
[51] A. Beggs,et al. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy , 2015, Oncoimmunology.
[52] J. Casanova,et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.
[53] M. Gerstein,et al. FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer , 2014, Genome Biology.
[54] Nicole A. Lavender,et al. Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer , 2014, BMC Medical Genomics.
[55] Lawrence C. LaPointe,et al. A panel of genes methylated with high frequency in colorectal cancer , 2014, BMC Cancer.
[56] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[57] Michael P. Schroeder,et al. IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.
[58] Semyon Kruglyak,et al. Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms , 2013, Bioinform..
[59] Vicent Pelechano,et al. An efficient method for genome-wide polyadenylation site mapping and RNA quantification , 2013, Nucleic acids research.
[60] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[61] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[62] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[63] Giovanni Parmigiani,et al. Integrating diverse genomic data using gene sets , 2011, Genome Biology.
[64] A. Toker,et al. NFAT proteins: emerging roles in cancer progression , 2009, Nature Reviews Cancer.
[65] J. Marshall,et al. Targeted therapy for colorectal cancer. , 2006, Current opinion in investigational drugs.
[66] L. Ellis,et al. Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.
[67] A. Marx,et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.
[68] J. L. Petersen,et al. REX1, a Novel Gene Required for DNA Repair* , 2003, Journal of Biological Chemistry.
[69] Hans Clevers,et al. Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.
[70] Ash A. Alizadeh,et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.
[71] Trevor J Pugh,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[72] Trevor J Pugh,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .